Top image

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

DATE
01 September 2016
PUBLICATION / RESOURCE TYPE
T1
TOPIC
  • Mirna
  • Clinical Trials
  • Mesothelioma

Summary

The results of this first-in-man study of TargomiRs showed that a dose of 5 × 10⁹ TargomiRs per week was well tolerated and was accompanied by early signs of antitumour activity. This study provides important safety data and shows encouraging response and survival in patients with malignant pleural mesothelioma. 

Source: Lancet Oncol 2017Available online 1 September 2017

Full text available here, with permission of fellow Sydney Catalyst member Nico van Zandwijk, ADRI.

 

Back to list